EGFR and neoplasm: Diverging from canonical NK cell effector functions, amphiregulin (AREG) acts as an epidermal growth factor receptor (EGFR) ligand, driving tumor progression by promoting cell survival, proliferation, and immune tolerance.[25, 26, 27, 28] Its upregulation in tumors also contributes to therapeutic resistance, positioning AREG as a mediator of both tumor aggression and therapy evasion.[27, 29, 30, 31] This dual role–directly fueling tumorigenesis while impairing treatment efficacy–establishes AREG as a multifaceted therapeutic target.